2022
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Bikdeli B, Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology 2022, 7: 747-759. PMID: 35648414, DOI: 10.1001/jamacardio.2022.1292.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsRandomized clinical trialsAcute VTE treatmentDose adjustmentOral anticoagulantsLow-intensity treatmentPrimary preventionLarge registriesVTE treatmentHigh-risk medical patientsStable atherosclerotic vascular diseaseHigh-risk cancer patientsLarge randomized clinical trialsSecondary VTE preventionPeripheral artery diseaseAtherosclerotic vascular diseaseDaily clinical practiceRoutine practice patternEvidence of safetyRecent revascularizationStroke preventionVTE preventionArtery diseaseMedical patientsCancer patientsProceedings From a National Heart, Lung, and Blood Institute and the Centers for Disease Control and Prevention Workshop to Control Hypertension
Commodore-Mensah Y, Loustalot F, Himmelfarb CD, Desvigne-Nickens P, Sachdev V, Bibbins-Domingo K, Clauser SB, Cohen DJ, Egan BM, Fendrick AM, Ferdinand KC, Goodman C, Graham GN, Jaffe MG, Krumholz HM, Levy PD, Mays GP, McNellis R, Muntner P, Ogedegbe G, Milani RV, Polgreen LA, Reisman L, Sanchez EJ, Sperling LS, Wall HK, Whitten L, Wright JT, Wright JS, Fine LJ. Proceedings From a National Heart, Lung, and Blood Institute and the Centers for Disease Control and Prevention Workshop to Control Hypertension. American Journal Of Hypertension 2022, 35: 232-243. PMID: 35259237, PMCID: PMC8903890, DOI: 10.1093/ajh/hpab182.Peer-Reviewed Original ResearchConceptsHypertension controlBlood pressureHypertension treatmentBlood InstituteNational HeartSelf-measured BP monitoringDisease controlCommunity-clinical linkagesModifiable risk factorsMore cardiovascular eventsAge-adjusted proportionSurgeon General's CallTeam-based careHigh-quality health carePublic health messagingCardiovascular eventsStroke preventionControl hypertensionBP monitoringHeart diseaseRisk factorsUS adultsClinical supportHealth messagingSocial determinants
1997
Warfarin use among patients with atrial fibrillation.
Brass L, Krumholz H, Scinto J, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997, 28: 2382-9. PMID: 9412618, DOI: 10.1161/01.str.28.12.2382.Peer-Reviewed Original ResearchConceptsAtrial fibrillationAdditional vascular risk factorsConnecticut Peer Review OrganizationRate of strokeVascular risk factorsStroke preventionWarfarin anticoagulationChart reviewElderly patientsRelative contraindicationPeer review organizationsRisk factorsMedicare patientsAnticoagulationHigh riskPatientsWarfarinFibrillationStrokeContraindicationsAspirinReview organizationsPopulation sampleHospitalizationMonths